Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate versus methotrexate + leflunomide in psoriatic arthritis
2018-002362-39Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Methotrexate monotherapy with Methotrexate + leflunomide combination (2 arms). Primary endpoint: PASDAS score at 16 weeks. Started Jul 2018; status: completed.
02
Drugs
methotrexateleflunomide
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-002362-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002362-39.